Literature DB >> 15689753

Unilateral acoustic neuromas: long-term hearing results in patients managed with fractionated stereotactic radiotherapy, hearing preservation surgery, and expectantly.

Vincent Y W Lin1, Craig Stewart, Julia Grebenyuk, May Tsao, David Rowed, Joseph Chen, Julian Nedzelski.   

Abstract

INTRODUCTION: Hearing preservation is invariably a consideration when exploring treatment options for acoustic neuromas. We reviewed the long-term hearing results of patients who were treated using 1) hyperfractionated stereotactic radiotherapy (HSR), 2) hearing preservation tumor excision surgery (HPTES), and 3) expectantly (no treatment). METHODS AND MATERIALS: Single institution retrospective chart review of 42 patients managed with HSR (1993-2003), 113 patients in whom HPTES was carried out, and 86 patients who were untreated (1974-2003). Hearing levels were graded according to the Gardner-Robertson classification.
RESULTS: The percent of patients managed with HSR initially who had serviceable hearing (class 1-2) was 68.8%. This fell to 6.7% in the follow-up interval. Of the group treated with HPTES, 100% had preoperative serviceable hearing. This dropped to 15.9% in the follow-up interval. The percent of patients managed expectantly who initially had serviceable hearing was 77.3%. This dropped to 33.3% during the follow-up interval. Mean follow-up periods were 4.0, 9.5, and 6.8 years in the HSR, HPTES, and expectant groups, respectively.
CONCLUSIONS: Hearing acuity statistically worsened over the long term (P < .01) in all three groups. There was a significant proportion of patients in whom hearing deteriorated from serviceable to nonserviceable hearing (P < .01) during the follow-up interval. The decline was most significant in the groups treated with HPTES and HSR compared with the group treated expectantly (P < .05). Hearing outcomes, in our experience, continue to be poor, but this is especially so in patients treated with HPTES or HSR.

Entities:  

Mesh:

Year:  2005        PMID: 15689753     DOI: 10.1097/01.mlg.0000154736.38904.c3

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

1.  Systematic Review of Hearing Preservation in Observed Vestibular Schwannoma.

Authors:  Martin Reznitsky; Per Cayé-Thomasen
Journal:  J Neurol Surg B Skull Base       Date:  2019-03-01

2.  Hypofractionated stereotactic radiotherapy of acoustic neuroma: volume changes and hearing results after 89-month median follow-up.

Authors:  Manfred Kranzinger; Franz Zehentmayr; Gerd Fastner; Gerhard Oberascher; Florian Merz; Olaf Nairz; Hassan Rahim; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2014-03-18       Impact factor: 3.621

3.  Tumor-volume changes after radiosurgery for vestibular schwannoma: implications for follow-up MR imaging protocol.

Authors:  O W M Meijer; E J Weijmans; D L Knol; B J Slotman; F Barkhof; W P Vandertop; J A Castelijns
Journal:  AJNR Am J Neuroradiol       Date:  2008-02-22       Impact factor: 3.825

4.  Systematic Review of Hearing Preservation After Radiotherapy for Vestibular Schwannoma.

Authors:  Adam R Coughlin; Tyler J Willman; Samuel P Gubbels
Journal:  Otol Neurotol       Date:  2018-03       Impact factor: 2.311

5.  Hearing preservation surgery in acoustic neuroma. Slow progress and new strategies.

Authors:  A Mazzoni; F Biroli; C Foresti; A Signorelli; C Sortino; E Zanoletti
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-04       Impact factor: 2.124

6.  Hearing preservation surgery in acoustic neuroma: long-term results.

Authors:  A Mazzoni; E Zanoletti; V Calabrese
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-04       Impact factor: 2.124

Review 7.  Efficacy and comorbidities of hypofractionated and single-dose radiosurgery for vestibular schwannomas: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Sergio Guadix; Anjile An; Drew Wright; Paul J Christos; Susan Pannullo; Andrew Brandmaier; Jonathan P S Knisely; Philip E Stieg; Rohan Ramakrishna
Journal:  Neurooncol Pract       Date:  2021-02-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.